BarbaraJeanHaleyMDFACP

Oncology • Dallas, TX

Breast Cancer, Hematologic Oncology

Professor Internal Medicine Hematology Oncology

Join to view full profile

Dr. Haley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haley's full profile

Already have an account?

Office
5323 Harry Hines Blvd
Dallas, TX 75390
Phone+1 214-645-8600

Education & Training

University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1976 - 1979
University of Texas Southwestern Medical SchoolClass of 1976

Certifications & Licensure

TX State Medical License 1976 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
Terminated
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) Start of enrollment: 2014 Jan 24
Completed
Phase 1
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

16 citations
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska
NPJ Breast Cancer. 2021-10-05
397 citations
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura J. van't Veer
The New England Journal of Medicine. 2016-07-06
397 citations
HER-2 gene amplification can be acquired as breast cancer progresses.
Songdong Meng, Debasish Tripathy, Sanjay Shete, Raheela Ashfaq, Barbara Haley
Proceedings of the National Academy of Sciences of the United States of America. 2004-06-22

Journal Articles

Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the in Vitro Integrity of T-cells from Cancer Patients
Kevin Courtney, Yull Arriaga, Barbara Haley, John C Mansour, Ponciano D Cruz, David Harker, Farshid Araghizadeh, Clinical Cancer Research

Press Mentions

Drugs Reprogram Genes in Breast Tumors to Prevent Endocrine ResistanceMay 14th, 2019
Researchers Uncover Mutated Genes Involved in Lung Cancer; One Affects NonsmokersOctober 24th, 2017